Navigation Links
Research: Dosage of Morphine for ill Newborns Still too Imprecise
Date:12/22/2009

LEIDEN, The Netherlands, December 22 /PRNewswire/ -- Dosage recommendations for newborns being cared for in an intensive care unit will in the future most likely be based on more individual characteristics than just body weight. This is the result of a study conducted by the Dutch Top Institute Pharma in which Leiden University (Prof M. Danhof) and the Rotterdam Erasmus Medical Centre/Sophia Children's Hospital (Prof D. Tibboel) are represented.

Catherijne Knibbe, clinical pharmacologist from the Leiden/Amsterdam Centre for Drug Research of Leiden University: "For morphine the preliminary study results show that for example a quarter of the current standard dose is sufficient for premature babies. The Erasmus MC/Sophia Children's Hospital had already noted in practice that some babies experienced withdrawal symptoms after long-term treatment with morphine. Now research has shown that the required amount of morphine can vary greatly per baby."

The dosage for children is often adjusted solely according to body weight, but that now seems to be insufficient. Knibbe said about the common used sedative midazolam: "A healthy child may be prescribed far more midazolam than for example a child with the same body weight lying in the intensive care unit with a severe infection. This study provides guidelines for arriving at a dosage recommendation that is adjusted better to the individual child. This is an enormous advance." According to Knibbe, this information is very important for doctors, as well as for pharmaceutical companies, which have been required for the past two years to conform to stricter European legislation for medicinal products for children.

This study required an intensive collaboration between clinical pharmacologists and pediatricians from the various institutes using modern methods like PK/PD modeling. Complex computer models can determine the correct dosage from small quantities of blood, taking into account the child's specific characteristics. Knibbe: "We know too little about the effects of medicinal products on children, especially newborns. Although we actually need more information than for adults. Children change so rapidly. In the first year of life the child changes each week, and responds differently and breaks down medicinal products differently. I think that these study results will mean that in some cases children will receive less medication, and thus fewer adverse effects will develop, while the child will still be treated well. I consider that a major benefit: for doctors, but most especially for the children and their parents."

The Top Institute Pharma is a collaboration between universities, university medical centers and pharmaceutical companies. This intensive collaboration accelerates research into new medicinal products and a better use of medication. The Dutch Ministry of Public Health, Welfare and Sport supports the Top Institute Pharma.

For more information, please contact Albert Reinders: +31-6-53184737.

SOURCE Top Institute Pharma


'/>"/>
SOURCE Top Institute Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ
2. Important Step Forward in Osteoarthritis Research: Bioactive Collagen Peptides Stimulate the Regeneration of Cartilage Tissue
3. Setting the Benchmark for Winery Tasting Room Research: An Emerging Region Gets a Global Perspective
4. New Weapon in BioDefense Research: NanoLogix Kit Speeds Rapid Diagnostics of Anthrax and Bubonic Plague
5. Encouraging high-risk research: DFG approves funding for 2 new Reinhart Koselleck projects
6. U-M research: New plastic is strong as steel, transparent
7. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
8. Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding
9. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
10. ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets
11. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software ... State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , ... Tremblay, President and COO of STACS DNA. “In further expanding our capacity as a ...
(Date:6/23/2016)...  Blueprint Bio, a company dedicated to identifying, protecting ... has closed its Series A funding round, according to ... "We have received a commitment from Forentis Fund that ... meet our current goals," stated Matthew Nunez . ... complete validation on the current projects in our pipeline, ...
Breaking Biology Technology:
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/22/2016)... March 22, 2016 ... Sensors Market for Consumer Industry by Type (Image, ... Application (Communication & IT, Entertainment, Home Appliances, ... Forecast to 2022", published by MarketsandMarkets, the ... to reach USD 26.76 Billion by 2022, ...
Breaking Biology News(10 mins):